• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4594883)   Today's Articles (8)   Subscriber (49330)
For: Demuth HU, Glund K, Banke-Bochita J, Rost KL, Fischer S, Hanefeld M, McIntosh CH, Pederson RA. Dipeptidyl peptidase IV (DP IV)-modulations as treatment of impaired glucose tolerance and niddm. ACTA ACUST UNITED AC 2000. [DOI: 10.1016/s0167-0115(00)80032-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Number Cited by Other Article(s)
1
von Geldern TW, Trevillyan JM. “The next big thing” in diabetes: clinical progress on DPP-IV inhibitors. Drug Dev Res 2006. [DOI: 10.1002/ddr.20138] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
2
Haffner CD, McDougald DL, Reister SM, Thompson BD, Conlee C, Fang J, Bass J, Lenhard JM, Croom D, Secosky-Chang MB, Tomaszek T, McConn D, Wells-Knecht K, Johnson PR. 2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV. Bioorg Med Chem Lett 2005;15:5257-61. [PMID: 16168640 DOI: 10.1016/j.bmcl.2005.08.050] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2005] [Revised: 08/12/2005] [Accepted: 08/15/2005] [Indexed: 11/18/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA